Characteristics and prognosis of glomangiopericytomas: A systematic review.

Head Neck

Department of Pathology, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Incheon, Republic of Korea.

Published: September 2017

Background: Glomangiopericytoma belongs to the category of borderline/low-malignant-potential tumors of the sinonasal tract, but no studies about prognosis have been reported.

Methods: To define the characteristics of glomangiopericytoma and to identify its prognostic factors, a systematic review was performed. A total of 337 cases of glomangiopericytomas were analyzed.

Results: Patients with glomangiopericytoma demonstrating resection margin involvement and receiving radiotherapy/chemotherapy had a significantly worse disease-free survival time (P =  .014 and .006, respectively). Patients with glomangiopericytoma had a tendency toward longer overall survival when they were diagnosed at a younger age (≤60 years; P = .001), did not demonstrate marginal involvement (P = .032), recurrence/metastasis (P = .002), or radiotherapy/chemotherapy (P = .010), and had a right-sided tumor (P < .001), actin-immunopositivity (P < .001), and CD34-/BCL2-immunonegativities (P = .002 and .019, respectively). By multivariate analysis, actin (P < .001) and CD34 (P = .002) immunostaining were significantly related to the overall survival of patients with glomangiopericytoma.

Conclusion: Actin and CD34 immunostaining could be used as independent prognostic indicators of glomangiopericytomas.

Download full-text PDF

Source
http://dx.doi.org/10.1002/hed.24818DOI Listing

Publication Analysis

Top Keywords

systematic review
8
patients glomangiopericytoma
8
characteristics prognosis
4
prognosis glomangiopericytomas
4
glomangiopericytomas systematic
4
review background
4
glomangiopericytoma
4
background glomangiopericytoma
4
glomangiopericytoma belongs
4
belongs category
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!